Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Tranexamic Acid in Hemorrhage: NCT06345833 Clinical Landscape Report 2026
18 September 2026
NCT06345833 clinical landscape for Hemorrhage: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SR-604 in Hemophilia B: NCT06349473 Clinical Landscape Report 2026
18 September 2026
NCT06349473 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
EN-001 (Encell) in Muscular Dystrophy, Duchenne: NCT06328725 Clinical Landscape Report 2026
18 September 2026
NCT06328725 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LNP-1265/REGV-131 in Hemophilia B: NCT06379789 Clinical Landscape Report 2026
18 September 2026
NCT06379789 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Motixafortide in Acute Chest Syndrome: NCT06506461 Clinical Landscape Report 2026
18 September 2026
NCT06506461 clinical landscape for Acute Chest Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GEN-6050X in Muscular Dystrophy, Duchenne: NCT06392724 Clinical Landscape Report 2026
18 September 2026
NCT06392724 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albutrepenonacog alfa in Hemophilia B: NCT06399289 Clinical Landscape Report 2026
18 September 2026
NCT06399289 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Captopril in Muscular Dystrophy, Duchenne: NCT06485661 Clinical Landscape Report 2026
18 September 2026
NCT06485661 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Satralizumab in Muscular Dystrophy, Duchenne: NCT06450639 Clinical Landscape Report 2026
18 September 2026
NCT06450639 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tranexamic Acid in Anemia: NCT06519422 Clinical Landscape Report 2026
18 September 2026
NCT06519422 clinical landscape for Anemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Osivelotor in Anemia, Sickle Cell: NCT06507904 Clinical Landscape Report 2026
18 September 2026
NCT06507904 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Hydroxycarbamide in Stroke: NCT06526117 Clinical Landscape Report 2026
18 September 2026
NCT06526117 clinical landscape for Stroke: endpoints, sponsor, phase, geography, readouts, asset context and development white space.